Erasmus School of Health Policy & Management
Visiting fellow | Health Economics (HE)
- l.timmers@eshpm.eur.nl
More information
Work
- Sabine Vogler, Verena Knoll, Anja Sonemann, Annemie Quanten, Roisin Adams, Tim de Jager, Marc Van de Casteele & Lonneke Timmers (2026) - Collaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policy - Applied Health Economics and Health Policy, 24 (6), 955-967 - doi: 10.1007/s40258-026-01057-z - [link]
- Diederik Brokkelkamp, Vivian Reckers-Droog, Lonneke Timmers & Pieter van Baal (2026) - Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands - PharmacoEconomics, 44 (10), 1267-1280 - doi: 10.1007/s40273-026-01637-w - [link]
- B. M.F. Penninx, C. E.M. Hollak, S. W. Tas, L. Timmers, S. J. de Visser & Z. L.E. van Kempen (2026) - From authorisation to clinical practice: evolution of the use of biological medicines according to the SmPC and guidelines (2006 to 2025) - European Journal of Clinical Pharmacology, 82 (7) - doi: 10.1007/s00228-026-04097-5 - [link]
- Bart M.F. Penninx, Sander W. Tas, Lonneke Timmers, Nicole C.A.J. van de Kar, Atse Huisman, Denise van den Berg, Zoé L.E. van Kempen & Carla E.M. Hollak (2026) - Rational use of expensive medicines in the Netherlands: strategies to improve effectiveness and reduce burden on patients and society – a narrative review - BMC Medicine, 24 (1) - doi: 10.1186/s12916-026-04897-7 - [link]
- Jesper T. Dros, Isabelle Bos, Christel E. van Dijk, Bert R. Meijboom, E. J.E. van der Hijden, L. Timmers & Robert A. Verheij (2025) - Shifting care from hospitals to general practice from the health insurers’ perspective: an interview study - Bmc Health Services Research, 25 (1) - doi: 10.1186/s12913-025-13650-4 - [link]
- Jan Willem Versteeg, Noraly Stam, Aukje K. Mantel-Teeuwisse, Lonneke Timmers, Wim Goettsch & Christine Leopold (2025) - Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands - International Journal of Technology Assessment in Health Care, 41 (1) - doi: 10.1017/S0266462325103267 - [link]
- Anne Willemsen, Maureen van Molken, Riam al Dulaimi, Hedi Schelleman, Wim G. Goettsch & Lonneke Timmers (2025) - Preparing for the EU HTA Regulation: Insights from the Dutch Perspective - Journal of Market Access and Health Policy, 13 (3) - doi: 10.3390/jmahp13030035 - [link]
- Sibren van den Berg, Carolina E. Hollak, Lonneke Timmers & Samuel J. de Visser (2025) - Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products - Value in Health, 28 (5), 692-698 - doi: 10.1016/j.jval.2025.03.004 - [link]
- Michiel Zietse, Roelof W.F. van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Jolanda E. de Boer, Rudy Dupree, Ron H.J. Mathijssen & Lonneke Timmers (2024) - Interchangeability of immune checkpoint inhibitors: an urgent need for action - The Lancet Oncology, 25 (11), e611-e616 - doi: 10.1016/S1470-2045(24)00212-2 - [link]
- R. Rozemeijer, W. P. van Bezouwen, N. D. van Hemert, J. A. Damen, S. Koudstaal, M. Stein, G. E. Leenders, L. Timmers, A. O. Kraaijeveld, K. Roes, P. Agostoni, P. A. Doevendans, P. R. Stella & M. Voskuil (2021) - Direct comparison of predictive performance of PRECISE-DAPT versus PARIS versus CREDO-Kyoto: a subanalysis of the ReCre8 trial - Netherlands Heart Journal, 29 (4), 201-214 - doi: 10.1007/s12471-020-01486-y - [link]
